01066威高股份 报.ppt

《01066威高股份 报.ppt》由会员分享，可在线阅读，更多相关《01066威高股份 报.ppt（166页珍藏版）》请在三一办公上搜索。

1、Shandong Weigao Group Medical Polymer Company Limited*山東威高集團醫用高分子製品股份有限公司,(a joint stock limited company incorporated in the Peoples Republic of China with limited liability),（在中華人民共和國註冊成立的股份有限公司）,(Stock Code 股票號碼:1066),Annual Report 2011 年報,*For identi cation purposes only,僅供識別,2,4,5,10,24,26,42,49

2、,65,68,69,71,72,74,1,CONTENTS 目錄PAGE(S)頁次,CORPORATE INFORMATIONCORPORATE PROFILECHAIRMANS STATEMENTMANAGEMENT DISCUSSION AND ANALYSISREPORT OF THE SUPERVISORY COMMITTEECORPORATE GOVERNANCE REPORTDIRECTORS,SUPERVISORS AND SENIOR MANAGEMENTREPORT OF THE DIRECTORSINDEPENDENT AUDITORS REPORTCONSOLIDATED

3、 STATEMENT OF COMPREHENSIVE INCOMECONSOLIDATED STATEMENT OF FINANCIAL POSITIONCONSOLIDATED STATEMENT OF CHANGES IN EQUITYCONSOLIDATED STATEMENT OF CASH FLOWSNOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS,公司資料公司簡介主席報告書管理層討論與分析監事會報告書企業管治報告董事、監事及高級管理人員董事會報告獨立核數師報告書綜合全面收入報表綜合財務狀況表綜合權益變動報表綜合現金流量報表綜合財務報表附

4、註,FINANCIAL SUMMARY,財務摘要,164,SHANDONG WEIGAO GROUP MEDICAL POLYMER COMPANY LIMITED 山東威高集團醫用高分子製品股份有限公司,2,CORPORATE INFORMATION 公司資料,DIRECTORS AND SUPERVISORSExecutive Directors,董事及監事執行董事,Mr.Mr.Mr.Mr.Mr.,Zhang Hua WeiMiao Yan GuoWang YiWang Zhi FanWu Chuan Ming,張華威先生苗延國先生王毅先生王志范先生吳傳明先生,Non-executive

5、DirectorsMr.Chen Xue LiMrs.Zhou Shu HuaMr.Li Bing YungIndependent non-executive DirectorsMr.Lo Wai HungMr.Li Jia MiaoMrs.Fu Ming ZhongSupervisorsMs.Bi Dong MeiMr.Miao Hai ShengMs.Chen Xiao YunCORPORATE INFORMATIONRegistered office and principal place of businessin the Peoples Republic of China(the“P

6、RC”)312 Shi Chang RoadWeihaiShandong ProvincePRCPrincipal place of business in Hong Kong801,Chinachem Century Tower178 Gloucester RoadWanchaiHong KongCompany secretaryMs.Wong Miu Ling,Phillis,ACISANNUAL REPORT 2011 年報,非執行董事陳學利先生周淑華女士李炳容先生獨立非執行董事盧偉雄先生李家淼先生付明仲女士監事畢冬梅女士苗海生先生陳曉雲女士公司資料中華人民共和國（中國）註冊辦事處及主要

7、營業地點中國山東省威海市世昌大道312號香港主要營業地點香港灣仔告士打道178號華懋世紀廣場801室公司秘書黃妙玲女士ACIS,1.,1.,2.,2.,3,CORPORATE INFORMATION 公司資料,Compliance officerMr.Zhang Hua WeiAudit committeeMr.Lo Wai HungMr.Li Jia MiaoMrs.Fu Ming ZhongMrs.Zhou Shu HuaRemuneration committeeMr.Lo Wai HungMr.Li Jia MiaoMrs.Fu Ming ZhongMrs.Zhou Shu HuaAu

8、thorised representativesMr.Zhang Hua WeiMs.Wong Miu Ling,PhillisAuditorsDeloitte Touche TohmatsuCertified Public AccountantsHong Kong share registrars and transfer officeTricor Standard Limited26/F,Tesbury Centre28 Queens Road EastWanchaiHong KongPrincipal bankersAgriculture Bank of China,Weihai Bra

9、nchBank of China,Weihai BranchWebsite of the CStock Code1066,監察主任張華威先生審核委員會盧偉雄先生李家淼先生付明仲女士周淑華女士薪酬委員會盧偉雄先生李家淼先生付明仲女士周淑華女士授權代表張華威先生黃妙玲女士核數師德勤關黃陳方會計師行執業會計師香港股份過戶登記處卓佳標準有限公司香港灣仔皇后大道東28號金鐘匯中心26樓主要往來銀行中國農業銀行威海市分行中國銀行威海市分行本公司網址股份代號1066,SHANDONG WEIGAO GROUP MEDICAL POLYMER COMPANY LIMITED 山東威高集團醫用高分子製品股份有限

10、公司,海市。,I.,I.,II.,II.,III.,III.,4,CORPORATE PROFILE 公司簡介,SHANDONG WEIGAO GROUP MEDICALPOLYMER COMPANY LIMITEDShandong Weigao Group Medical Polymer Company Limited(the“Company”)and its subsidiaries(together the“Group”)is principally engaged in the research and development,production and sale of single

11、-use medical devices.TheGroup has a wide range of products,which includes:i)consumables(infusion sets,syringes,medical needles,blood bags,pre-filled syringes,blood sampling products,andother consumables);ii)orthopedic materials and iii)bloodpurification consumables.The Company is recognised as anind

12、ustrialization base to commercialise products developedby the State High-tech Research and Development(863)Program,the State High-tech Enterprise and the StateTechnology Center.The Groups main production facilities issituated in Weihai City in Shandong Province.The Group is incorporated in the Peopl

13、es Republic of China.The Group has an extensive sales network comprising 22sales offices,30 customer liaison centers and 111 municipalrepresentative offices.It has an extensive customer base of5,069 healthcare organizations and distributors,including2,951 hospitals,414 blood stations,622 other medic

14、al unitsand 1,082 trading companies.The Group produces a wide range of products in followingmajor categories,namely:Single use medical consumables and materials(including infusion(transfusion)sets,syringes,bloodbags and blood component segregator consumable,blood sampling products,prefilled syringes

15、 for pre-packmedication and medical needles which mainly includeintravenous needles,syringe needles,intravenouscatheter needles,blood sampling needles and irregularneedles;Orthopedic materials and instruments,including traumaproducts of steel plates and screws,spinal implants andartificial joints;an

16、dBlood purification consumables,including puncturen e e d l e s,e x t r a c o r p o re a l b l o o d c i rc u i t f o r b l o o dpurification sets,dialyzers and related consumables.ANNUAL REPORT 2011 年報,關於山東威高集團醫用高分子製品股份有限公司山東威高集團醫用高分子製品股份有限公 司（本 公 司）及 其 附 屬 公 司（統 稱本集團）主要從事研究及開發、生產及銷售一次性醫療器械。本集團提供不同

17、種類產品，包括：i)耗材（輸液器、注射器、醫用針製品、血袋、預充式注射器、採血產品及其他使用耗材）；ii)骨科材料及iii)血液淨化耗材。本公司為中國國家高技術研 究 發 展(863)計 劃 成 果 產 業 化 基 地、國家級高新技術企業、國家企業技術中心。本集團主要生產基地位於中國山東省威本集團在中華人民共和國註冊成立，擁有一個由22個銷售辦事處及30個客戶聯絡中心和111家城市代表處組成的龐大銷售網絡，並已建立廣泛的客戶基礎，其產品銷售予5,069家醫療單位和分銷商，其中包括醫院2,951家、血站414家、其他醫療機構622家和1,082家經銷商。本集團生產的多種產品，主要可分為以下系列，

18、即：一 次 性 使 用 醫 療 耗 材 及 原 料，其 中包 括 輸 液（血）器、注 射 器、血 袋 與血液成份分離耗材、採血系列耗材、用於藥品包裝的預充式注射器及醫用 針 製 品，主 要 包 括 靜 脈 針、注 射針、留置針、採血針、異形針等系列製品等；骨科材料及工具，主要包括鋼板、螺釘 等 創 傷 治 療 耗 材、脊 柱 系 列 耗 材及人工關節系列耗材；及血 液 淨 化 系 列 耗 材，主 要 包 括 穿 刺針、血液淨化裝置之體外循環管路、透析器等有關耗材。,%,5,CHAIRMANS STATEMENT 主席報告書,On behalf of the board of directors

19、(the“Board”)ofShandong Weigao Group Medical Polymer Company Limited,I would like to present the audited consolidated results ofthe Group for the year ended 31st December,2011(the“Year”).The Groups results in 2011 have continued togrow steadily,with prominent effect from the optimizationadjustment to

20、 product mix,which laid a foundation for ourfuture development.FINANCIAL SUMMARYD u r i n g t h e y e a r u n d e r re v i e w,t h e G ro u p re c o rd e dtur nover of approximately RMB3,180,577,000(2010:RMB2,462,557,000)for the year ended 31st December,2011,representing an increase of approximately

21、 29.2%over the previous year and profit attributable to equitys h a re h o l d e r s w a s a p p ro x i m a t e l y R M B3,462,172,000(2010:RMB799,072,000),representing an increase ofapproximately 333.3%over the previous year.Net profitattributable to the owner of the Company excludingextraordinary

22、item was RMB958,036,000(2010:RMB760,628,000)representing an increase of approximately26.0%over the previous year and basic earning per sharewas approximately RMB0.78.The growth in turnover andprofit attributable to shareholders have been mainly due toour strategy of optimizing the product mix,focusi

23、ng on thebusiness development of blood purification products andincreased the marketing and sales efforts on high value-added products.FINANCIAL HIGHLIGHT,本人欣然代表山東威高集團醫用高分子製品股份有限公司董事會（董事會）向股東提呈本集團截至二零一一年十二月三十一日止年度（本年度）的經審核綜合業績。本集團二零一一年度業績持續穩步 增 長，產 品 結 構 調 整 與 優 化 的 效 果 顯著，為未來發展奠定了基礎。財務摘要回顧年度內，本集團截至

24、二零一一年十二月三十一日止年度的營業額達到約人民幣3,180,577,000元（二 零 一 零 年：人 民幣2,462,557,000元），較 上 一 年 度 增 加約29.2%，而權益股東應佔溢利約為人民幣3,462,172,000元（二 零 一 零 年：人 民幣799,072,000元），較 上 一 年 度 上 升 約333.3%。不計特殊項目的本公司擁有人應佔純利為人民幣958,036,000元（二零一零年：人民幣760,628,000元），較上一年度上升約26.0%。每股基本盈利約為人民幣0.78元。營業額及股東應佔溢利增加主要因本集團按策略推進產品結構的優化調整，重點發展血液淨化產品

25、業務，增加高附加值產品的市場推介與銷售。財務概覽Audited經審核,2011二零一一年RMB000人民幣千元,2010二零一零年RMB000人民幣千元,Growth增長,TurnoverGross profit,營業額毛利,3,180,5771,760,116,2,462,5571,359,699,29.229.4,Net profit attributable to the owners ofthe Company excluding extraordinary,不計特殊項目的本公司擁有人,itemsNet profit attributable to shareholders,應佔純利股

26、東應佔純利,958,0363,462,172,760,628799,072,26.0333.3,SHANDONG WEIGAO GROUP MEDICAL POLYMER COMPANY LIMITED 山東威高集團醫用高分子製品股份有限公司,(1),(1),(2),(2),(3),(3),(4),(4),6,CHAIRMANS STATEMENT 主席報告書,BUSINESS REVIEWDuring the Year,the Group continued the strategy ofoptimizing the product mix,focusing on the businessd

27、evelopment of blood purification products and increasedthe marketing and sales efforts on high value-addedproducts such as intravenous catheters,non PVC infusionsets,specialized infusion set with dosage control device,achieving a continuous growth in turnover.Due to effectiveadjustments in product m

28、ix,the Group absorbed the impactof escalating raw materials and labour costs during the Year,and further increased the gross profit margin to 55.3%from55.2%in the previous year.The performance of the Group infour business segments was as follows:The growth momentum continued for consumables ofthe Gr

29、oup,reaching approximately RMB2,643,990,000for the year ended 31st December,2011,representingan increase of 27.3%when compared with the previousyear;The turnover of orthopaedic for the year wasapproximately RMB243,423,000,representing a growthof 38.9%when compared with the previous year.The Distribu

30、tion Joint Venture with Medtronic,Inc.inorthopaedic products contributed approximately a netprofit of RMB47,224,000 to the Group for the year,representing an increase of 7.0%when compared withthe previous year;The turnover of haemodialysis consumablesand equipment for the year was approximatelyRMB29

31、3,164,000,representing an increase of39.8%when compared with the previous year.Lossattributable to Weigao Nikkiso(Weihai)DialysisEquipment Co.,Ltd.(“Weigao Nikkiso”),which is51%held by the Group,amounted to approximatelyRMB6,601,000;andThe stent business of 山 東 吉 威 醫 療 製 品 有 限 公 司(Shandong JW Medica

32、l Products Company Limited)(“JW Medical”),a 50%jointly owned entity of theCompany,contributed approximately RMB106,443,000to the profit of the Group for the nine months ended30th September,2011.The Company disposed of its50%equity interest in JW Medical and an one-off profitcontribution of approxima

33、tely RMB2,568,534,000 wasrecognized by the Group.Biosensors International PteLtd.(“Biosensors”),which is 21.6%held by the Group,contributed approximately RMB4,195,000 to the profitof the Group.Excluding extraordinary items,Biosensorscontributed approximately RMB36,595,000 to the profitof the Group.A

34、NNUAL REPORT 2011 年報,業務回顧年內，本集團繼續按策略推進產品結構的優化調整，重點發展血液淨化產品業務，增加留置針、非PVC輸液器與特種流量監控輸液器等高附加值產品的市場推介與銷售，營業收入持續增長。由於產品結構的 有 效 調 整，本 集 團 消 化 了 年 內 原 材 料價格上漲與工資水平提高的成本上漲影響，進一步提升了毛利率水平，從去年的55.2%提升到55.3%。本集團四個業務部類取得了如下發展：本集團常規耗材醫療製品維持持續 增 長 態 勢，截 至 二 零 一 一 年 十 二月三十一日止年度營業額達人民幣 約2,643,990,000元，較 去 年 增 長27.3%；

35、骨科年度營業收入約人民幣2 4 3,4 2 3,0 0 0 元，較 去 年 增 長38.9%；與 美 敦 力 合 營 的 骨 科 產 品分銷公司年度內為本集團貢獻約人民 幣47,224,000元 淨 收 益，較 去 年增長7.0%；血液透析耗材與設備年度營業收入約人民幣293,164,000元，較去年增長39.8%，本 集 團 持 有51%股 權 的威高日機裝（威海）透析機器有限公司（威高日機裝）的應佔虧損約為人民幣6,601,000元；及本公司持有50%股權的山東吉威醫療 製 品 有 限 公 司（吉 威 醫 療）的心臟支架業務截至二零一一年九月三 十 日 止 九 個 月，為 本 集 團 的

36、利 潤貢獻約人民幣106,443,000元；本公司 出 售 其 於 吉 威 醫 療 的50%股 權，而本集團確認的一次性利潤貢獻約為 人 民 幣2,568,534,000元；本 集 團持 有21.6%股 權 的 新 加 坡 柏 盛 國 際有 限 公 司（新 加 坡 柏 盛）為 本 集團的利潤貢獻約為人民幣4,195,000元，不 計 特 殊 項 目 的 新 加 坡 柏 盛為本集團的利潤貢獻約為人民幣36,595,000元。,7,CHAIRMANS STATEMENT 主席報告書,BUSINESS REVIEW(continued)The Directors recommended the pa

37、yment of a final dividendof RMB0.03(2010:RMB0.075),which is subject to approvalby the shareholders of the Company(“Shareholders”)at theforthcoming general meeting.ANNUAL GENERAL MEETING AND CLOSUREOF REGISTER OF MEMBERSThe register of members of the Company will be closedfrom Saturday,21st April,201

38、2 to Monday,21st May,2012(both days inclusive),for the purpose of determiningshareholders entitlement to attend the forthcoming annualgeneral meeting(the“Annual General Meeting”),duringwhich period no transfer of shares of the Company willbe registered.In order to qualify for attending the AnnualGen

39、eral Meeting,shareholders should ensure that all transferdocuments,accompanied by the relevant share certificates,are lodged with the Companys branch share registrar,TricorStandard Limited at 26/F,Tesbury Centre,28 Queens RoadEast,Hong Kong for registration no later than 4:30 p.m.onFriday,20th April

40、,2012.In order to qualify for attending the annualgeneral meeting:,業務回顧（續）董事建議派付末期股息每股人民幣0.03元（二零一零年：人民幣0.075元），該項建議須經本公司股東（股東）在即將舉行的股東大會上批准後，方可作實。股東週年大會及暫停辦理股份過戶登記手續為確定股東出席應屆股東週年大會（股東 週 年 大 會）之 權 力，本 公 司 將 於 二 零一 二 年 四 月 二 十 一 日（星 期 六）至 二 零一二年五月二十一日（星期一）（包括首尾兩天）暫停股東名冊過戶登記，於該期間將不會辦理本公司股份過戶登記手續。為符合資格

41、出席股東週年大會，股東應確保所有過戶文件連同有關股票不遲於二零一二年四月二十日（星期五）下午四時三十分送交本公司的股份過戶登記分處卓佳標準有限公司，地址為香港皇后大道東28號 金 鐘 匯 中 心26樓，以 辦 理 登 記 手續。為符合資格出席股東週年大會：,Latest time to lodge in the transferinstrument accompanied bythe share certificates,4:30 p.m.,Friday,20th April,2012,交回過戶文件連同有關股票之最後期限,二零一二年四月二十日（星期五）,下午四時三十分,Closure of r

42、egister of members ofthe Company for attendance ofthe annual general meeting,Saturday,21st April,2012 toMonday,21st May,2012,本公司截止過戶登記以釐定出席股東週年大會之資格,二零一二年四月二十一日（星期六）至二零一二年,五月二十一日（星期一）,Latest time to lodge in the reply slip,4:30 p.m.,Monday,30th April,2012,交回回條之最後期限,二零一二年四月三十日,（星期一）下午四時三十分,Date of an

43、nual general meeting,Monday,21st May,2012,股東週年大會日期,二零一二年五月二十一日,（星期一）SHANDONG WEIGAO GROUP MEDICAL POLYMER COMPANY LIMITED 山東威高集團醫用高分子製品股份有限公司,8,CHAIRMANS STATEMENT 主席報告書,PROPOSED FINAL DIVIDEND AND CLOSUREOF REGISTER OF MEMBERSThe Board recommended a final dividend of RMB0.03 pershare(inclusive of t

44、ax).The total amount of final dividendsto be distributed shall be approximately RMB134,291,000,ofwhich dividends paid to non-resident corporate shareholderswill be subject to the corporate tax applicable on the PRCsourced income pursuant to the PRC Corporate IncomeTax Law and the Regulations on the

45、Implementation of thePRC Corporate Income Tax Law that became effective on1st January,2008 and the applicable tax rate is 10%.Thelisted issuer will be responsible for withholding the relevantamount of tax from the dividend payment and the dividendsto be received by the non-resident corporate shareho

46、lderswill be net of withholding tax.The proposal to declare andpay the final dividend will be submitted to the forthcomingAnnual General Meeting to be held on Monday,21st May,2012.Final dividend for non-listed shares will be distributedand paid in Renminbi whereas dividend for H shares will bedeclar

47、ed in Renminbi and paid in Hong Kong dollars.The register of members of the Company will be closed fromSaturday,26th May,2012 to Thursday,31st May,2012(bothdays inclusive)for the purpose of determining shareholdersentitlement to final dividend for the year ended 31stDecember,2011,during which period

48、 no transfer of sharesof the Company will be registered.In order to qualify forentitlement of final dividend,shareholders should ensurethat all transfer documents,accompanied by the relevantshare certificates,are lodged with the Companys branchshare registrar,Tricor Standard Limited at 26/F,TesburyC

49、entre,28 Queens Road East,Hong Kong for registrationno later than 4:30 p.m.on 25th May,2012.,建議末期股息及暫停辦理股份過戶登記手續董事會建議派付末期股息每股人民幣0.03元（含 稅）。將 分 派 的 末 期 股 息 總 額約 人 民 幣134,291,000元。其 中，根 據 於二 零 零 八 年 一 月 一 日 正 式 實 施 的中 國企 業 所 得 稅 法及中 國 企 業 所 得 稅 法實施條例，向非居民企業股東派發的股息如來源於中國境內的所得應當繳納企業所得稅，適用稅率為10%由上市發行人從股息

50、付款代扣代繳。非居民企業股東的股 息 將 先 扣 除 預 扣 稅。宣 派 和 支 付 末 期股息的建議將在即將於二零一二年五月二十一日（星期一）舉行的股東週年大會上提呈。非上市股份的末期股息將以人民幣派發和支付，而H股股息將以人民幣宣派和以港元支付。為確定股東收取截至二零一一年十二月三 十 一 日 止 年 度 之 末 期 股 息 之 權 利，本公司將於二零一二年五月二十六日（星期六）至二零一二年五月三十一日（星期四）（包括首尾兩天）暫停股東名冊過戶登記，於該期間將不會辦理本公司股份過戶登記手續。為符合資格收取末期股息，股東應確保所有過戶文件連同有關股票不遲於二零一二年五月二十五日下午四時三十分